Marinus Pharmaceuticals (NASDAQ:MRNS) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a $27.00 price target on the biopharmaceutical company’s stock.

MRNS has been the topic of several other research reports. Cantor Fitzgerald reiterated an overweight rating and issued a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. Oppenheimer reiterated a market perform rating and issued a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Robert W. Baird reiterated a neutral rating on shares of Marinus Pharmaceuticals in a report on Tuesday. StockNews.com cut Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, March 6th. Finally, Royal Bank of Canada reiterated a sector perform rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average target price of $16.07.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $1.38 on Tuesday. The stock’s fifty day moving average is $8.37 and its 200-day moving average is $8.36. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07. The stock has a market capitalization of $75.80 million, a PE ratio of -0.52 and a beta of 0.91. Marinus Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The business had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same quarter in the previous year, the company posted ($0.76) EPS. Equities research analysts expect that Marinus Pharmaceuticals will post -2.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Marinus Pharmaceuticals by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 2,673,231 shares of the biopharmaceutical company’s stock valued at $29,058,000 after buying an additional 95,756 shares during the period. Wellington Management Group LLP raised its position in shares of Marinus Pharmaceuticals by 54.8% during the fourth quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after purchasing an additional 85,455 shares during the period. Barclays PLC raised its position in shares of Marinus Pharmaceuticals by 747.4% during the fourth quarter. Barclays PLC now owns 76,372 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 67,360 shares during the period. Nuveen Asset Management LLC raised its position in shares of Marinus Pharmaceuticals by 1.1% during the fourth quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock worth $1,519,000 after purchasing an additional 1,475 shares during the period. Finally, Royal Bank of Canada raised its position in shares of Marinus Pharmaceuticals by 124.1% during the fourth quarter. Royal Bank of Canada now owns 15,364 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 8,507 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.